Provide Better Access to Diabetic Retinal Exams at the Point of Care with the WELCH ALLYN RETINAVUE Care Delivery Model

Help Members Close Care Gaps and Achieve Value-Based Care Measures

Patients living with diabetes should be examined for complications on an annual basis, but only 60% of patients comply.¹

Whether you’re performing diabetic retinal exams in the primary care office or in a mobile clinic, including the Welch Allyn RetinaVue care delivery model as part of your comprehensive diabetes management program can help:

Achieve up to 90% compliance in one year2
Improve total cost of care with early detection and treatment3
Improve HEDIS, Star and HCC risk factors

Are you ready to help preserve vision for patients living with diabetes? Connect with a rep to learn how the RetinaVue care delivery model can become an important component of your value-based care initiatives.

References

Diabetic Retinopathy Preferred Practice Pattern® from the American Academy of Ophthalmology, http://dx.doi.org/10.1016/j.ophtha.2019.09.025, ISSN 0161-6420/19. Accessed July 29, 2020.
Mansberger SL, Sheppler C, Barker G, et al. Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: A randomized clinical trial. JAMA Ophthalmol.
Newman, M. (2009) Fiscal Impact of AB 175: Analysis of the Cost Effectiveness of Store and Forward Teleophthalmology, Blue Sky Consulting Group for California Health Care Foundation, www.chcf.org/wp-content/uploads/2017/12/PDF-FiscalImpactAB175AnalysisTeleophthalmology.pdf.

Baxter, Hillrom, RetinaVue and Welch Allyn are trademarks of Baxter International Inc. or its subsidiaries. HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA). ALL RIGHTS RESERVED. US-FLC-147-230024 V1 02/23